Prednisone
Treatment for Interstitial Lung Disease And Pulmonary Sarcoidosis
Typical Dosage: 20-40 mg daily, tapered
Effectiveness
75%
Safety Score
50%
Clinical Trials
8
Participants
2M
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
20-40 mg daily, tapered
Time to Effect
Days to 2 weeks
Treatment Duration
Months to years
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$750
Side Effect Mgmt:$1,200
Total Annual:$2,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTOutcome-Based Costs
Cost per Responder
$2,800
Cost per Remission
$5,250
Prednisone Outcomes
for Interstitial Lung Disease And Pulmonary Sarcoidosis
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Remission Rate
+40%
Common Side Effects
Weight gain
+80%
Mood changes
+50%
Insomnia
+40%
Hyperglycemia
+30%
Increased infection risk
+20%
Osteoporosis (long-term)
+15%
Sources:
Active Clinical Trials
2 active trials recruiting for Prednisone in Interstitial Lung Disease And Pulmonary Sarcoidosis
Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis
NCT07668895NOT YET RECRUITINGPHASE2, PHASE3
126 participants
INTERVENTIONAL
Beijing, China
Started: Jul 1, 2026
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
NCT05841758RECRUITINGPHASE4
140 participants
INTERVENTIONAL
Avignon, France +20 more
Started: Jul 30, 2024
Completed Clinical Trials
4 completed trials for Prednisone in Interstitial Lung Disease And Pulmonary Sarcoidosis
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).
NCT02200146COMPLETEDPHASE3
94 participants
INTERVENTIONAL
Milan, Italy
Started: Mar 1, 2009
A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis
NCT03324503COMPLETEDNA
8 participants
INTERVENTIONAL
Birmingham, United States +19 more
Started: Dec 8, 2017
Diffuse Fibrotic Lung Disease
NCT00000596COMPLETEDPHASE2
INTERVENTIONAL
Started: Jun 1, 1978
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
NCT03793439COMPLETEDPHASE1
5 participants
INTERVENTIONAL
Portland, United States
Started: May 15, 2019